---
layout: default
title: VisuEvo® vs Cationorm® – Head-to-Head Trial Summary (Fogagnolo et al., 2020)
permalink: /clinical/visuevo-vs-cationorm-2020/
---

# VisuEvo® vs Cationorm®  
**Head-to-Head Trial – Fogagnolo et al., Clinical Ophthalmology 2020**

**Quick Summary for Clinicians** (2-minute read)

Multicenter, double-blind, randomized, 12-week cross-over trial (no washout)  
N = 72 patients with dry eye disease (54 evaporative DED, 18 non-evaporative DED)  
VisuEvo® (VSE) compared to Cationorm® (CTN) – 6 weeks each in randomized sequence

**Primary endpoint – TBUT**  
Baseline: 3.2 ± 1.5 s  
Intermediate (week 2): ~4.5 s both arms  
Final (week 6): 5.4 ± 2.4 s (VSE) vs 6.0 ± 3.1 s (CTN)  
Within-group improvement: p < 0.001  
Between-group difference: p = 0.63 (final visit) – **non-inferiority confirmed** (95% CI −1.19 to +0.05 > −0.5 s margin)

**OSDI score**  
Baseline: 37 ± 12 (severe)  
Final: 19 ± 13 (VSE) / 19 ± 14 (CTN) – ~18-point reduction (p < 0.001)

**Other key results**  
Osmolarity: 314 ± 23 → ~305–307 mOsm/L  
Ocular surface staining: ~15% improvement  
Incomplete blinks: significant reduction (p < 0.001 overall)  
Tear cytokines & lipids: reduced (IFN, sphingosine, S1P – p values 0.06 to <0.0014 in whole population)

**Safety**  
Transient blurred vision: 11 (CTN only), 10 (VSE only), 16 (both)  
No serious adverse events

**Conclusion from paper**  
“VSE was non-inferior to CTN in restoring tear film composition, increasing its stability and reducing ocular surface damage in evaporative and non-evaporative DED patients.”

Full open-access article:  
[PMC7308118 – Clinical Ophthalmology 2020;14:1651–1663](https://pmc.ncbi.nlm.nih.gov/articles/PMC7308118/)

*Educational summary for healthcare professionals. Paraphrased and cited from original publication. Not for promotional use.*

---

**Figure 1 – Study Flow Diagram**  
![Study Flow](https://pmc.ncbi.nlm.nih.gov/articles/PMC7308118/bin/OPTH-14-1651-g0001.jpg)  
Cross-over design without washout period

**Figure 2 – Bland-Altman Plot (TBUT comparison)**  
![Bland-Altman TBUT](https://pmc.ncbi.nlm.nih.gov/articles/PMC7308118/bin/OPTH-14-1651-g0002.jpg)  
Points clustered around zero difference → comparable performance between treatments

---

**Key Table – Main Endpoints (selected data)**

| Parameter              | Baseline          | Intermediate (VSE / CTN) | Final (VSE / CTN)     | p-value (VSE vs CTN) |
|------------------------|-------------------|---------------------------|------------------------|-----------------------|
| TBUT (seconds)         | 3.2 ± 1.5        | 4.5 ± 1.9 / 4.5 ± 1.9    | 5.4 ± 2.4 / 6.0 ± 3.1 | 0.10 / 0.63          |
| OSDI score             | 37 ± 12          | 23 ± 15 / 23 ± 15        | 19 ± 13 / 19 ± 14     | 0.43 / 0.44          |
| Tear osmolarity (mOsm/L) | 314 ± 23       | 305 ± 16 / 305 ± 16      | 305 ± 15 / 307 ± 20   | 0.46 / 0.60          |

**Tear Cytokines & Lipids (subgroup analysis – selected significant reductions)**

| Parameter                  | Baseline (mean ± SD) | Final (mean ± SD) | Significance (whole population) |
|----------------------------|----------------------|-------------------|----------------------------------|
| IFN (pg/mL)                | 2.81 ± 2.09         | 1.69 ± 1.97      | p < 0.05                        |
| Sphingosine (pmol/mg)      | 537 ± 435           | 179 ± 135        | p < 0.05                        |
| Sphingosine 1-phosphate    | 4 ± 2               | 2 ± 1            | p < 0.05                        |

(Full Table 2 shows additional reductions in IL-6, IL-8, ceramides, sphingomyelin – no significant difference between VSE and CTN.)

**STAR TAKEAWAY**  
VisuEvo® demonstrated **non-inferiority** to Cationorm® across all evaluated parameters, including tear film stability, symptom relief, osmolarity normalization, and reduction of pro-inflammatory cytokines and lipids.

[Back to Clinical Evidence](/clinical/) | [Back to SGBioPharma](/sgbiopharma/) | [Home](/)
<!-- Build trigger - added Jan 27 2026 -->
